Blue Jet Healthcare Ltd. (BLUEJET) fundamentals
Blue Jet Healthcare Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as BLUEJET (ISIN INE0KBH01020). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Blue Jet Healthcare Ltd. does
Blue Jet Healthcare Limited is an India-based company, specializing in manufacturing integrated contrast media, artificial sweeteners and its salts, as well as niche pharmaceutical intermediaries and active pharmaceutical ingredients (APIs). The Company serves as a business-to-business (B2B) company. Its integrated contrast media intermediate product categories include x-ray contrast media intermediates and MRI contrast media intermediates. Its x-ray contrast media intermediates include non-ionic APIs and ionic APIs. It manufactures saccharin and supplies to healthcare, pharma, animal feed, food and beverages industries globally. The Company's offerings include insoluble saccharin, saccharin sodium and insoluble saccharin. Its advance pharmaceutical intermediates and API products include Vanillic Acid, Docusate Sodium and TosMIC. It offers end-to-end integrated solutions from process development to commercialization of NCEs, advance intermediates, APIs and building blocks.
Valuation and market data
| Last close | ₹575.00 |
|---|---|
| Market capitalisation | ₹9,972 crore |
| Enterprise value | ₹9,965 crore |
| P/E (TTM) | 40.24 |
| Price to book | 7.33 |
| Price to sales (TTM) | 6.04 |
| Book value per share | ₹78.42 |
| Dividend yield | 20.87% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Nov 01 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,016 crore | ₹333 crore | ₹248 crore | 14.29 |
| Mar 2025 | ₹1,076 crore | ₹406 crore | ₹305 crore | 17.59 |
| Mar 2024 | ₹740 crore | ₹220 crore | ₹164 crore | 9.44 |
| Mar 2023 | ₹745 crore | ₹217 crore | ₹160 crore | 9.23 |
| Mar 2022 | ₹703 crore | ₹243 crore | ₹182 crore | 10.47 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jul 2026:
| Promoters | 73.2% |
|---|---|
| Foreign institutions (FII) | 0.6% |
| Mutual funds | 5.2% |
| Other domestic institutions | 3.9% |
| Retail and others | 17.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.